ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Taltz (ixekizumab) — U.S. revenue by Year
Taltz (ixekizumab) — U.S. revenue ($M) ($M)
Eli Lilly Taltz (ixekizumab) — U.S. revenue: $2,333M in FY2025, up 8.4% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Taltz (ixekizumab) — U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,333 | +8.4% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 2,152 | +17.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,832 | +6.2% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 1,725 | +11.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 1,542 | +19.7% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 1,289 | +26.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 1,017 | +37.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 739 | +52.0% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 486 | +338.6% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 111 | – | Form 10-K (filed 2019-02-19) ↗ |
Breakdown
What makes up taltz (ixekizumab) — U.S. revenue
Cite this data
StockData. (2026). Eli Lilly Taltz (ixekizumab) — U.S. revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-taltz-us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.